Brand & Product Security

Articles

Eohilia, a corticosteroid developed specifically to treat eosinophilic esophagitis, is comprised of a novel formulation of budesonide taken twice daily for 12 weeks in patients 11 years of age and older.

FDA Approves Eohilia as the First Oral Treatment for Eosinophilic Esophagitis 

Technavio analysis notes that an increase drug patent expirations could be a contributing factor. 

Forecast Predicts Generic Drug Market Will Grow Upwards of $175B Over the Next Three Years

The FDA placed a full clinical hold on magrolimab for hematologic cancers after data showed the drug in combination with azacitidine plus Venclexta increased the risk of death related to infections and respiratory failure in patients with acute myeloid leukemia.

Gilead Halts Development of Magrolimab in Hematologic Cancers Due to Increased Death Risk, Futility

Phase III CheckMate -77T trial data show statistically significant improvements in event-free survival with Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo in the treatment of resectable stage IIA to IIIB non-small cell lung cancer.  

Regulatory Submissions Filed for Opdivo Regimen in Resectable Non-Small Cell Lung Cancer 

BioNTech SE and Duality Biologics Co's BNT325/DB-1305 is a next-generation antibody-drug conjugate that targets the TROP2 protein, which is overexpressed across various tumor types. 

Novel ADC in Trials for Ovarian, Fallopian Tube, Primary Peritoneal Cancers Gets FDA Fast Track Designation

Arexvy was the first FDA-approved respiratory syncytial virus (RSV) vaccine to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

FDA to Review Application to Expand Indication of RSV Vaccine Arexvy to Adults Aged 50-59 Years

A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?

The Correlation Between a New York State Law Repeal and Vaccine Coverage in Schools

UV1 is an off-the-shelf vaccine that has demonstrated a survival benefit in combination with ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with unresectable malignant pleural mesothelioma.

FDA Grants Fast Track Designation to Cancer Vaccine for Malignant Pleural Mesothelioma  

Allarity reached an agreement with Novartis in 2018 to license dovitinib, a small molecule multi-tyrosine kinase inhibitor under evaluation for the treatment of renal cell carcinoma.

Allarity Loses Rights to Cancer Drug Dovitinib After Missing Payments to Novartis

Treatment with the novel engineered T-cell receptor produced an overall response rate of about 39% in patients with heavily pretreated synovial sarcoma.

Legal & Regulatory